FH RAKOTONJAFINIARIVO, S NIRY MANANTSOA, HJ HERINIAINA, MK RANAIVOSOA, A RASAMINDRAKOTROKA
{"title":"马达加斯加塔那那利佛生化实验室SARS-CoV-2患者的肌钙蛋白水平","authors":"FH RAKOTONJAFINIARIVO, S NIRY MANANTSOA, HJ HERINIAINA, MK RANAIVOSOA, A RASAMINDRAKOTROKA","doi":"10.53346/wjbpr.2023.4.1.0046","DOIUrl":null,"url":null,"abstract":"Objective: To describe the epidemiological and biological profile and the cardiac troponin level of patients infected with SARS-CoV-2 who underwent troponinemia testing. Methods: Retrospective descriptive and analytical study during a period of 5 months in which were included all patients with COVID-19, hospitalized at the Joseph Ravoahangy Andrianavalona University Hospital (CHU-JRA) in Antananarivo Madagascar and having performed a high sensitive cardiac troponin (hs-cTn) determination at the Biochemistry Laboratory of the same Hospital. . Study parameters were demographics, reasons for admission, medical history, oxygen saturation and patient outcome and paraclinical parameters were troponin level, chest CT image. Results: Among the 103 cases collected, 46.6% had an elevated hs-cTn level and mostly patients aged 71 to 80 years. Of the 43 patients who died, 60.5% were men. Most had cardiovascular risk factors, oxygen desaturation and critical parenchymal damage on chest CT. There was a significant difference between hs-cTn positivity and female gender and that therapeutic management was corrected after the troponin result. Among the deceased patients, 28 (65,11%) have high troponin levels. Conclusion: Troponin testing is important in patients with COVID-19 to detect the risk of mortality due to cardiovascular complications.","PeriodicalId":267430,"journal":{"name":"World Journal of Biological and Pharmaceutical Research","volume":"9 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Troponin level in SARS-CoV-2 patients in a biochemistry lab in Antananarivo Madagascar\",\"authors\":\"FH RAKOTONJAFINIARIVO, S NIRY MANANTSOA, HJ HERINIAINA, MK RANAIVOSOA, A RASAMINDRAKOTROKA\",\"doi\":\"10.53346/wjbpr.2023.4.1.0046\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To describe the epidemiological and biological profile and the cardiac troponin level of patients infected with SARS-CoV-2 who underwent troponinemia testing. Methods: Retrospective descriptive and analytical study during a period of 5 months in which were included all patients with COVID-19, hospitalized at the Joseph Ravoahangy Andrianavalona University Hospital (CHU-JRA) in Antananarivo Madagascar and having performed a high sensitive cardiac troponin (hs-cTn) determination at the Biochemistry Laboratory of the same Hospital. . Study parameters were demographics, reasons for admission, medical history, oxygen saturation and patient outcome and paraclinical parameters were troponin level, chest CT image. Results: Among the 103 cases collected, 46.6% had an elevated hs-cTn level and mostly patients aged 71 to 80 years. Of the 43 patients who died, 60.5% were men. Most had cardiovascular risk factors, oxygen desaturation and critical parenchymal damage on chest CT. There was a significant difference between hs-cTn positivity and female gender and that therapeutic management was corrected after the troponin result. Among the deceased patients, 28 (65,11%) have high troponin levels. Conclusion: Troponin testing is important in patients with COVID-19 to detect the risk of mortality due to cardiovascular complications.\",\"PeriodicalId\":267430,\"journal\":{\"name\":\"World Journal of Biological and Pharmaceutical Research\",\"volume\":\"9 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Biological and Pharmaceutical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.53346/wjbpr.2023.4.1.0046\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Biological and Pharmaceutical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53346/wjbpr.2023.4.1.0046","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Troponin level in SARS-CoV-2 patients in a biochemistry lab in Antananarivo Madagascar
Objective: To describe the epidemiological and biological profile and the cardiac troponin level of patients infected with SARS-CoV-2 who underwent troponinemia testing. Methods: Retrospective descriptive and analytical study during a period of 5 months in which were included all patients with COVID-19, hospitalized at the Joseph Ravoahangy Andrianavalona University Hospital (CHU-JRA) in Antananarivo Madagascar and having performed a high sensitive cardiac troponin (hs-cTn) determination at the Biochemistry Laboratory of the same Hospital. . Study parameters were demographics, reasons for admission, medical history, oxygen saturation and patient outcome and paraclinical parameters were troponin level, chest CT image. Results: Among the 103 cases collected, 46.6% had an elevated hs-cTn level and mostly patients aged 71 to 80 years. Of the 43 patients who died, 60.5% were men. Most had cardiovascular risk factors, oxygen desaturation and critical parenchymal damage on chest CT. There was a significant difference between hs-cTn positivity and female gender and that therapeutic management was corrected after the troponin result. Among the deceased patients, 28 (65,11%) have high troponin levels. Conclusion: Troponin testing is important in patients with COVID-19 to detect the risk of mortality due to cardiovascular complications.